- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06241222
Origin of the Neonatal Gut Microbiota and Probiotic Intervention
Study Overview
Detailed Description
Study design and participants A total of 30 samples were obtained from pregnant individuals receiving antenatal care at the 1st Affiliated Hospital of Jinan University. Informed consent was obtained from pregnant women (at least 32 gestational weeks) who met the inclusion criteria. Newborns were followed until 14 days after natural delivery. Pregnant inclusive criteria were: 1. Chinese woman who is pregnant with a single fetus; 2. First pregnancy and term delivery. Newborns' inclusive criteria were: 1. Normal weight (>2500 g, <4000 g); 2. Term Infant (>37 weeks, <42 weeks). 3. Natural birth. Pregnanct exclusive criteria were: 1. Gastrointestinal disease or family history; 2. Vaginitis before pregnancy; 3. Antibiotic usage during pregnancy; 4. Hypertension, Diabetes Mellitus, Hyperthyroidism, Hypothyroidism, Autoimmune Disease, or Other Endocrine and Metabolic Disease; 5. Gestational Hypertensive Disease, Gestational Diabetes Mellitus or Other Gestational Disease; 6. Transfusion History, Organ Transplantation History or Immunotherapy History. Newborn's exclusive criteria were: 1. Abnormal weight (>4000 g, <2500 g); 2. With Congenital Diseases;3. Intrapartum Fetal Complication.
Probiotic management In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery, and those in the control group took no pills.
Fecal, vaginal secretion, placental, and meconium collection Fecal collection Feces from pregnant patients were collected twice-between weeks 32 and 34 and before natural labor. Feces collected at weeks 32-34 were collected internally, thereby avoiding contamination with foreign material. The feces were stored in a domestic refrigerator and transferred to the laboratory freezer at -80 ºC for 24 hours. Feces collected before labor were obtained in the hospital and transferred to the laboratory freezer within 30 min of collection.
Vaginal secretion collection Vaginal secretions were collected twice between weeks 32 and 34 and before natural labor. The pregnant woman was asked to not engage in sexual behavior, clean the vulva, clean the vagina, or use vaginal medicine within 48 hours before sample collection. Vaginal secretions before natural labor were collected before membrane rupture occurred. The samples were transferred to the laboratory freezer within 30 min of collection, thereby avoiding contamination by foreign material.
Placenta collection Placenta samples ranging from the entire umbilical cord to 3 cm were collected by stripping the amniotic membrane after natural birth. The blood was rinsed with sterile saline. Four to six pieces of placenta were sampled from the fetal surface. Each piece had a volume of approximately 1 cm3. The placenta sample was transferred to the laboratory freezer within 30 min of collection.
Meconium collection Meconium was collected three times on the 1st day, the 3rd day, and the 14th day after natural delivery On the 1st day and 3rd day, meconium was collected internally, thereby avoiding contamination with foreign material in the hospital, and was transferred to the laboratory freezer within 30 min of collection. On the 14th day, meconium was collected, stored in a domestic refrigerator, and then transferred to a laboratory freezer within 24 hours of collection.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Zhe Li
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Pregnant inclusive criteria were:
- Chinese woman who is pregnant with a single fetus;
- First pregnancy and term delivery.
Newborns' inclusive criteria were:
- Normal weight (>2500 g, <4000 g);
- Term Infant (>37 weeks, <42 weeks).
- Natural birth.
Pregnancy exclusive criteria were:
- Gastrointestinal disease or family history;
- Vaginitis before pregnancy;
- Antibiotic usage during pregnancy;
- Hypertension, Diabetes Mellitus, Hyperthyroidism, Hypothyroidism, Autoimmune Disease, or Other Endocrine and Metabolic Disease;
- Gestational Hypertensive Disease, Gestational Diabetes Mellitus or Other Gestational Disease;
- Transfusion History, Organ Transplantation History or Immunotherapy History.
Newborn's exclusive criteria were:
- Abnormal weight (>4000 g, <2500 g);
- With Congenital Diseases;3. Intrapartum Fetal Complication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: control group
pregnancies in control group need no intervention.
|
|
Experimental: probiotics group
pregnancies in probiotics group need probiotics management
|
In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group.
After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd.
Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
16S rRNA amplicon sequencing of the V4 region
Time Frame: 12 months
|
Difference analysis of each group was performed.
All the measurement data are presented as the mean ± standard error.
Assessments of Operational Taxonomic Units differences in the probiotic group and control group were performed using independent sample t tests, and P < 0.05 was considered to indicate statistical significance.
Other outcomes were analyzed using multiple linear regression.
All data were analyzed using SPSS 23.0 statistical software (SPSS, Inc., Chicago, IL, USA).
|
12 months
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Chen Y, Li Z, Tye KD, Luo H, Tang X, Liao Y, Wang D, Zhou J, Yang P, Li Y, Su Y, Xiao X. Probiotic Supplementation During Human Pregnancy Affects the Gut Microbiota and Immune Status. Front Cell Infect Microbiol. 2019 Jul 16;9:254. doi: 10.3389/fcimb.2019.00254. eCollection 2019.
- Yang P, Li Z, Tye KD, Chen Y, Lu T, He Z, Zhou J, Xiao X. Effects of an orally supplemented probiotic on the autophagy protein LC3 and Beclin1 in placentas undergoing spontaneous delivery during normal pregnancy. BMC Pregnancy Childbirth. 2020 Apr 15;20(1):216. doi: 10.1186/s12884-020-02905-z.
- Huang T, Li Z, Tye KD, Chan SN, Tang X, Luo H, Wang D, Zhou J, Duan X, Xiao X. Probiotic supplementation during pregnancy alters gut microbial networks of pregnant women and infants. Front Microbiol. 2022 Dec 1;13:1042846. doi: 10.3389/fmicb.2022.1042846. eCollection 2022.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- [2019]no.11EthicsCommittee
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Microbiota
-
Microbio Co LtdCompleted
-
University of California, Los AngelesCompleted
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompleted
-
Manchester University NHS Foundation TrustUniversity of ManchesterRecruiting
-
University of ManitobaAlmond Board of CaliforniaTerminated
-
Kimberly-Clark CorporationWithdrawn
-
Afyonkarahisar Health Sciences UniversityNot yet recruiting
-
Hadassah Medical OrganizationBar-Ilan University, IsraelWithdrawn
-
Samara State Medical UniversityRecruitingOral MicrobiotaRussian Federation
-
Shanghai 10th People's HospitalRecruitingGut MicrobiotaChina
Clinical Trials on Probiotic Blend Oral Tablet
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingMicrobiota | Postoperative RecoveryChina
-
Instituto de Genética Médica y MolecularIndustrial Farmacéutica Cantabria, S.A.Completed
-
Lallemand Health SolutionsKGK Science Inc.Completed
-
Mednax Center for Research, Education, Quality...Phoenix Children's Hospital; Banner University Medical CenterCompletedTotal Parenteral Nutrition | Necrotizing Enterocolitis of NewbornUnited States
-
Kırıkkale UniversityCompletedSmoking | Gingivitis; Chronic
-
Universitat Internacional de CatalunyaCompletedMucositis | Peri-implantitis
-
Universidade do Extremo Sul Catarinense - Unidade...RecruitingObesity | Overweight and Obesity | Obesity; Endocrine | Overweight, Obesity and Other HyperalimentationBrazil
-
Bausch Health Americas, Inc.CompletedFunctional Gastrointestinal DisordersUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)Completed
-
Universidade do Extremo Sul Catarinense - Unidade...RecruitingIrritable Bowel SyndromeBrazil